Just as a murky pond hides treasures beneath its surface, subjective cognitive decline (SCD) is an enigmatic state that can signal the onset of more serious cognitive impairment in patients with Parkinson’s disease (PD). Like an elusive clue, SCD refers to self-reported cognitive decline without any detectable signs of objective cognitive dysfunction. Although research on PD-SCD has been limited, recent studies have revealed a potential association between SCD and brain metabolic changes in PD patients, suggesting early pathological alterations. Additionally, PD patients with SCD may be more likely to face future cognitive impairments. To shine light on this mysterious condition, researchers aim to establish a definitive definition and evaluation guideline for SCD in PD. Through larger sample sizes and longitudinal investigations, they hope to uncover earlier indicators of cognitive decline before it reaches the stage of mild cognitive impairment (MCI), allowing for timely intervention and support. To delve deeper into this captivating field of study, explore the underlying research!
Cognitive impairment in patients with Parkinson’s disease (PD) worsens the prognosis of PD and increases caregivers’ burden and economic consequences. Recently, subjective cognitive decline (SCD), which refers to self-reported cognitive decline without detectable objective cognitive dysfunction, has been regarded as an at-risk state of mild cognitive impairment (MCI) and a prodromal stage for dementia in Alzheimer’s disease (AD). However, studies on PD-SCD have thus far been scarce, and at present there is no consensus regarding the definition of SCD nor a gold standard as an evaluation tool. The present review aimed to look for an association between PD-SCD and objective cognitive function and found that PD with SCD occurred with brain metabolic changes, which were consistent with early aberrant pathological changes in PD. Moreover, PD patients with SCD were likely to progress to future cognitive impairment. It is necessary to establish a guideline for the definition and evaluation of SCD in PD. A larger sample size and more longitudinal investigations are needed to verify the predictive effectiveness of PD-SCD and to detect earlier subtle cognitive decline before MCI.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.
